$1.98
-0.02 (-1.00%)
Open$2.00
Previous Close$2.00
Day High$2.05
Day Low$1.95
52W High$3.19
52W Low$1.32
Volume—
Avg Volume1.07M
Market Cap159.53M
P/E Ratio—
EPS$-0.09
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+1,476.3% upside
Current
$1.98
$1.98
Target
$31.21
$31.21
$17.92
$31.21 avg
$31.70
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.10M | 52.30M | 361.03M |
| Net Income | -6,776,075 | -5,895,086 | 15.50M |
| Profit Margin | -12.5% | -11.9% | 4.3% |
| EBITDA | -4,141,382 | -3,803,105 | 29.24M |
| Free Cash Flow | — | — | 6.36M |
| Rev Growth | +3.5% | +3.5% | +17.6% |
| Debt/Equity | — | — | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $213.76 | +2.08% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $330.33 | -0.13% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $130.28 | -0.17% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $429.32 | -1.15% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $641.69 | +1.81% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.86 | -0.15% | 66.6 | 38.43B |